Regend Therapeutics

Regend Therapeutics focuses on the human organ regenerative medicine business

ActiveBioTechHealth CareTherapeutics

Updated: Feb 17, 2026 ·

Recent News & Mentions

Feb 11, 2026FundingRegend Therapeutics - Series C

Financial History

Regend Therapeutics has raised $50.6M across 1 funding round. Most recently, it raised $50.6M Series C in February 2026.

Total Raised

$50.6M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Feb 11, 2026	$50.6M Series C		Angel Plus China, Fir Creek Capital, Gongqingcheng Fuhui, Hefei High-tech VC, Hefei Industry Investment Group, Tasly Capital, Yuze Capital

Financial History

Regend Therapeutics has raised $50.6M across 1 funding round.

Total Raised

$50.6M

Valuation

N/A

Frequently Asked Questions

How much funding has Regend Therapeutics raised?

Regend Therapeutics has raised $50.6M in total across 1 funding round.

Who are Regend Therapeutics's investors?

Regend Therapeutics's investors include Angel Plus China, Fir Creek Capital, Gongqingcheng Fuhui, Hefei High-tech VC, Hefei Industry Investment Group, Tasly Capital, Yuze Capital.

Frequently Asked Questions

How much funding has Regend Therapeutics raised?

Regend Therapeutics has raised $50.6M in total across 1 funding round.